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Abstract
Osteoblasts express two key molecules for osteoclast differentiation, receptor activator of
NF-κB ligand (RANKL) and osteoprotegerin (OPG), a soluble decoy receptor for RANKL.
RANKL induces osteoclastogenesis, while OPG inhibits it by blocking the binding of RANKL
to RANK, a cellular receptor of RANKL.OPG-deficient (OPG±/±) mice exhibit severe alveolar
bone loss with enhanced bone resorption. WP9QY (W9) peptide binds to RANKL and blocks
RANKL-induced osteoclastogenesis. W9 is also reported to stimulate bone formation in
vivo. Here, we show that treatment with W9 restores alveolar bone loss inOPG±/±mice by
suppressing osteoclastogenesis and enhancing osteoblastogenesis. Administration of W9
or risedronate, a bisphosphonate, toOPG±/±mice significantly decreased the osteoclast
number in the alveolar bone. Interestingly, treatment withW9, but not risedronate, enhanced
Wnt/β-catenin signaling and induced alveolar bone formation inOPG±/±mice. Expression
of sclerostin, an inhibitor of Wnt/β-catenin signaling, was significantly lower in tibiae of
OPG±/±mice than in wild-typemice. Treatment with risedronate recovered sclerostin expres-
sion inOPG±/±mice, whileW9 treatment further suppressed sclerostin expression. Histo-
morphometric analysis confirmed that bone formation-related parameters inOPG±/±mice,
such as osteoblast number, osteoblast surface and osteoid surface, were increased byW9
administration but not by risedronate administration. These results suggest that treatment of
OPG±/±mice with W9 suppressed osteoclastogenesis by inhibiting RANKL signaling and
enhanced osteoblastogenesis by attenuating sclerostin expression in the alveolar bone.
Taken together, W9 may be a useful drug to prevent alveolar bone loss in periodontitis.
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Introduction
Osteoclasts, bone-resorbing multinucleated cells, differentiate from the monocyte/macrophage
lineage under the tight control of osteoblast-lineage cells (hereafter called osteoblasts) [1, 2].
Osteoblasts express two key molecules for osteoclast differentiation, receptor activator of NF-
κB ligand (RANKL) [3, 4] and osteoprotegerin (OPG) [5, 6]. RANKL is a member of the
tumor necrosis factor (TNF) superfamily that binds to its receptor RANK expressed on osteo-
clasts and their progenitors [1, 2]. The interaction of RANKL with RANK is required for osteo-
clast differentiation and activation. OPG, a soluble decoy receptor for RANKL, inhibits
osteoclastogenesis by blocking the RANKL-RANK interaction. OPG-deficient (OPG–/–)
mice exhibit severe osteopenia with enhanced bone resorption [7, 8]. Bone formation of
OPG–/–mice is also enhanced through the coupling mechanism [9]. We and others have
reported that OPG–/–mice demonstrate severe alveolar bone loss [10, 11].
Alveolar bone, a component of periodontal tissues, supports teeth and protects them from
biting forces. Periodontitis is an inflammatory disease characterized by destruction of peri-
odontal tissues including alveolar bone [12]. Bacterium-derived factors, such as lipopolysac-
charide (LPS) and antigens, activate the innate and acquired immune system, respectively
[13]. Activation of both systems induces local inflammatory reactions. Eventually, a cascade of
inflammatory reactions leads to osteoclastogenesis and subsequent progression of bone loss,
which in turn causes the loss of teeth.
Treatments of humans and animals with antiresorptive agents, such as bisphosphonates
and denosumab, an anti-RANKL neutralizing monoclonal antibody, have been shown to
inhibit bone resorption associated with osteoporosis and periodontitis [11, 14–16]. Adminis-
tration of bisphosphonates significantly prevented alveolar bone loss in a rat periodontitis
model [14]. It was also reported that osteoporotic patients treated with bisphosphonates
tended to have fewer missing teeth than untreated [15, 16]. We reported that treatment of
OPG–/–mice with risedronate, a bisphosphonate, or anti-RANKL antibody significantly
reduced the osteoclast number in the alveolar bone and protected the alveolar bone loss [11].
These findings indicate that the OPG–/–mouse is a useful model for screening antiresorptive
agents.
Bone resorption is reported to be tightly coupled with bone formation [17–20]. This cou-
pling phenomenon is clearly observed in OPG–/–mice [7, 9]. Bone formation in OPG–/–mice is
accelerated concomitantly by the increased bone resorption. Treatment of OPG–/–mice with
risedronate, and that of wild-type (WT) mice with anti-RANKL antibodies inhibited not only
bone resorption but also bone formation [9, 20]. Several factors are proposed as coupling
factors that facilitate the transition from bone resorption to bone formation. Sphingosine-
1-phosphate (S1P) secreted from osteoclasts promotes osteoblast differentiation [21]. It is also
proposed that some factors embedded in bone matrix, such as transforming growth factor β
and bone morphogenetic proteins, are released as coupling factors during osteoclastic bone
resorption [22]. Wnt/β-catenin signaling in osteoblasts promotes bone formation in vivo [23].
We have proposed that osteocytes contribute to the coupling process through the regulation of
expression of sclerostin (encoded by the Sost gene), an antagonist of Wnt/β-catenin signaling
[24]. Expression of sclerostin was markedly suppressed in OPG–/–mice [25], and administra-
tion of anti-RANKL antibodies to OPG–/–mice enhanced sclerostin expression [24]. Adminis-
tration of bisphosphonates to mice prevented ovariectomy-induced bone loss, and also
enhanced sclerostin expression [26]. These results suggest that osteoclastic bone resorption
may regulate sclerostin expression by osteocytes.
WP9QY (W9) is a peptide designed to be structurally similar to one of the cysteine-rich
domains in TNF receptor type I [27]. W9 was demonstrated to bind not only TNF-α but also
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RANKL, and to inhibit RANKL-induced osteoclastogenesis in vitro [28]. Administration of
W9 increased the bone mineral density (BMD) through inhibition of osteoclastogenesis in sev-
eral mouse bone-loss models. In addition, W9 stimulated osteoblast differentiation in osteo-
blast cultures in part through the production of BMP-2 [29]. Therefore, it is proposed that W9
binds RANKL expressed on osteoblasts and induces RANKL-mediated reverse signals in oste-
oblasts to induce BMP-2 production. Local administration of W9 also augmented BMP-2-
induced ectopic bone formation in mice [30]. These reports suggest that W9 administration
increases BMD through both inhibition of bone resorption and induction of bone formation.
Here, we examined the effects of W9 administration on alveolar bone loss in OPG–/–mice.
Treatment of OPG–/–mice with W9 suppressed osteoclastogenesis by inhibiting RANKL sig-
naling and enhanced osteoblastogenesis by attenuating sclerostin expression in alveolar bone.
Thus, we propose that W9 may be a useful drug to prevent alveolar bone loss in periodontitis.
Materials andmethods
Mice and reagents
OPG–/–mice (genetic background C57BL/6) [8] were purchased from CLEA Japan (Tokyo,
Japan). OPG–/–mice were bred with WT mice (strain C57BL/6) obtained from Japan SLC (Shi-
zuoka, Japan). Twelve-week-old male OPG–/– and OPG+/+ littermates (WT) were used in this
study. The number of mice in the respective group was determined according to our previous
studies [11, 24]. All procedures for animal care were approved by the Animal Management
Committee of Matsumoto Dental University (permit number: 267) and performed accord-
ingly. W9 peptide [29] was provided by Oriental Yeast (Tokyo). Risedronate was obtained
from LKT laboratories (St. Paul, MN). Other chemicals and reagents were of analytical grade.
Treatments ofOPG±/± andWTmice withW9 and risedronate
W9 or risedronate, a nitrogen-containing bisphosphonate, was subcutaneously administered
to 12-week-old OPG–/–mice (n = 7 for each group) (Fig 1A). W9 was administered three times
a day at 10 mg/kg/dose body weight for the first 5 days [29]. Risedronate was administered
once a day at 0.1 mg/kg body weight for the first 3 days. Saline (vehicle) was administered to
12-week-old OPG–/– and WT mice similarly to W9 administration. Calcein (a fluorescent dye
for labeling of bones) was injected twice subcutaneously into mice on day 1 and day 4. Mice
were sacrificed on day 6 by injection of excess amounts of pentobarbital.
Analysis of alveolar bone loss by in vivo μCT images
Maxillae of WT and OPG–/–mice (n = 7) were analyzed on day 6 using an in vivo μCT appara-
tus (R_mCT; Rigaku, Tokyo) at 85 kV and 160 μA with a copper filter of 0.1 mm using 512
projections over 30 s [11]. The voxel resolution was 20 μm. The images reconstructed were
observed using i-view software (J. Morita Mfg., Kyoto, Japan). The distance between the
cemento–enamel junction (CEJ) and alveolar bone crest (ABC) was measured at 8 points for
each molar [first molar (M1) to third molar (M3)] of maxillae as alveolar bone loss, a clinical
parameter in periodontitis (Fig 1C). The distance of 8 points was summed as alveolar bone
loss.
Bonemorphometry of interradicular septum in first molars
Mandibles were subjected to the three-dimensional (3D) μCT analysis using micro focus X-
ray CT (ScanXmate-A080; Comscantecno, Yokohama, Japan). A sagittal surface that pene-
trated the medial and distal root canals of the M1 of mandibles was used for observation. The
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Fig 1. Effects of W9 and risedronate administration on alveolar bone loss inOPG-/-mice. (A) Experimental design.W9 or vehicle
was administered subcutaneously three times/day for the first 5 days to 12-week-old maleOPG±/±mice. Risedronate was administered
once a day at 0.1 mg/kg body weight for the first 3 days. Saline (vehicle) was administered toOPG±/± andWTmice similarly to W9
administration. Each group of mice was sacrificed on day 6 (n = 7). (B) Three-dimensional μCT images of maxillae fromWTmice and
OPG±/±mice. (C) A schematic diagram for measurement of the distance betweenCEJ and ABC on μCT images. (D) The CEJ-ABC
WP9QY peptide recovers alveolar bone loss
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region of interest (ROI) was manually established in the alveolar bone area of the M1 interradi-
cular septum (Fig 1E, left panel). The inferior border of the ROI was determined by drawing a
line between the root apexes of the medial and distal roots of the M1 [11]. The CT images were
used to reconstruct 3D images. Bone morphometric analysis to determine BV/TV (n = 7) was
performed using analytic software (TRI/3D-BON; Ratoc System Engineering, Tokyo).
Histomorphometry of alveolar bone
To examine bone resorption and formation in the alveolar bone, the mandibles were recovered
from WT and OPG–/–mice. Mandibles were fixed in 70% ethanol and embedded in glycol-
methacrylate without decalcification. Sections were prepared and stained with Villanueva
Goldner to discriminate between mineralized and unmineralized bone, and to identify cellular
components. The ROI was manually established in the alveolar bone area of the M1 interradi-
cular septum (Fig 2A, left panel). Quantitative histomorphometric analysis was performed in a
blind fashion (n = 5). Nomenclature and units were used according to the guidelines of the his-
tomorphometry nomenclature committee of the American Society for Bone and Mineral
Research [31].
Immunocytochemistry of alveolar bone
The dissected maxillae were used for immunohistological analysis. They were fixed in 4%
paraformaldehyde (PFA), decalcified with 10% EDTA, and embedded in paraffin. Histological
sections were prepared and stained for TRAP, a marker of osteoclasts. For immunohistochem-
ical staining, histological sections were incubated with the anti-osterix antibody (ab22552,
abcam, Cambridge, UK), anti-ALP antibody (ab108337, abcam), anti-β-catenin antibody
(ab32572, abcam), or anti-sclerostin antibody (AF1589, R&D Systems, Minneapolis, MN) at
4˚C overnight. After washing, the sections were incubated with the horseradish peroxidase
(HRP)-conjugated secondary antibody. The HRP-conjugated antibody was visualized with a
3,3’-diaminobenzidine tetrahydrochloride (DAB) kit (DAKO, Carpinteria, CA). The sections
were counterstained with hematoxylin. The number of TRAP- or osterix-, sclerostin-positive
cells was measured by histomorphometry, in the alveolar bone of maxillae, and expressed as
cells/bone surface or cells/bone area. The surface and area of bone in the alveolar bone of max-
illae were measured by ImageJ software (NIH, Bethesda, MD, USA; http://rsb.info.nih.gov/ij).
Measurements of a serummarker
Mouse serum samples were collected and subjected to ELISA analysis as described previously
[11]. Serum activities of ALP were determined with an ALP assay kit (Wako, Osaka, Japan).
Statistical analysis
The experiments of measuring of distances between CEJ and ABL using μCT images and bone
volume of M1 interradicular septum were repeated twice and similar results were obtained.
The results are expressed as the mean ± SD for five or more animals. The significance of differ-
ences between two groups was determined by Student’s t-test and that among 3 or more
groups was determined by ANOVA with a Fisher’s protected least significant difference test.
distance inWTmice and inOPG±/±mice. (E) μCT images of the interradicular septum of the first molar (M1) in mandibles fromWTmice
(an area surrounded by a white dotted line) andOPG±/±mice. (F) Bone volume/tissue volume (BV/TV) wasmeasured in the M1
interradicular septum fromWTmice and inOPG±/±mice treated with or withoutW9 and risedronate (n = 7). Data are expressed as the
mean ± SD in (D) and (F). *: p<0.05. Scale bar, 0.5 mm.
https://doi.org/10.1371/journal.pone.0184904.g001
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Fig 2. Effects of W9 and risedronate administration on alveolar bone resorption inOPG-/-mice. (A) Histological analysis of
the interradicular septum of the first molar (M1) in mandibles fromWTmice andOPG±/±mice treated with and withoutW9 or
risedronate. Mandible tissues were subjected to Villanueva bone staining. (B) Osteoclasts in the M1 interradicular septum from
WT andOPG±/±mice. Multinucleated osteoclasts are surrounded by white dotted lines. (C) TRAP staining of maxillae fromWT
and ofOPG±/±mice. TRAP-positive osteoclasts (red cells) were observed in the M1 interradicular septum in alveolar bone areas.
(D) The number of TRAP-positive cells/bone surface (N/mm) was determined in the M1 interradicular septum (n = 5). Data are
expressed as themeans ± SD. *: p<0.05. Scale bar, 50 μm.
https://doi.org/10.1371/journal.pone.0184904.g002
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Results
W9 restores alveolar bone loss inOPG±/±mice
We first examined whether administration of W9 suppresses the alveolar bone loss in
OPG–/–mice using μCT (Fig 1). W9 or risedronate was injected into 12-week-old OPG–/–mice
or WT mice, and alveolar bone loss was evaluated on day 6 (Fig 1A). The alveolar bone surface
in OPG–/–mice was much rougher than that in WT mice (Fig 1B). OPG–/–mice also exhibited
severe alveolar bone resorption associated with exposed dental roots of molars. Administration
of W9 or risedronate to OPG–/–mice markedly reduced the cortical porosity on day 6 (Fig 1B).
The distance between the cemento–enamel junction (CEJ) and alveolar bone crest (ABC)
(CEJ-ABC distance), used as an indicator of alveolar bone loss, was determined on 3D images
of maxillae (Fig 1C). The CEJ-ABC distance in OPG–/–mice was significantly greater than that
in WT mice (Fig 1D). Administration of W9 or risedronate to OPG–/–mice significantly
reduced the CEJ-ABC distance compared with vehicle-treated OPG–/–mice. To further evalu-
ate the resorption of alveolar bone in OPG–/–mice, we measured bone volume of the M1 inter-
radicular septum, a part of alveolar bone. μCT analysis revealed that bone volume/tissue
volume (BV/TV) in the septum was significantly lower in OPG–/–mice than in WT mice (Fig
1E and 1F). Administration of W9 or risedronate significantly increased BV/TV of this region
in OPG–/–mice, but not in WT mice (Fig 1F and S3 Fig). These results suggest that the alveolar
bone loss in OPG–/–mice is restored by administration of W9 or risedronate.
W9 suppresses osteoclastogenesis in alveolar bone ofOPG±/±mice
We next examined bone tissues of the M1 interradicular septum using histomorphometric
analysis (Fig 2). Villanueva bone staining revealed that osteocytes of the M1 interradicular sep-
tum were arranged the layered structures (Fig 2A, left panel), indicating that the interradicular
septum was developed by lamella bone formation. Bone area/tissue area (B.Ar/T.Ar) of the
septum was significantly lower in OPG–/–mice than in WT mice (Fig 2A, Table 1). Administra-
tion of W9 or risedronate to OPG–/–mice significantly increased B.Ar/T.Ar of the M1 interra-
dicular septum.
Osteoclastogenesis was also examined in the M1 interradicular septum, in which osteoclasts
were hardly observed in WT mice (Fig 2B, left panel). Osteoclasts were indicated by white dot-
ted lines. The osteoclast number was significantly higher in OPG–/–mice than in WT mice (Fig
2B, Table 1). The size of osteoclasts in OPG–/–mice was larger than that in WT mice (Fig 2B).
Administration of W9 and risedronate to OPG–/–mice significantly decreased the osteoclast
number compared with vehicle administration, without apparent effects on the size of osteo-
clasts (Fig 2B, Table 1). Osteoclastogenesis in the M1 interradicular septum was also evaluated
by tartrate-resistant acid phosphatase (TRAP, a marker of osteoclasts) staining (Fig 2C).
TRAP-positive osteoclasts and cement lines were more abundant in OPG–/–mice than in WT
mice, suggesting that both osteoclast formation and osteoclast function in the septum were
accelerated in OPG–/–mice. Administration of W9 and risedronate significantly decreased
the number of TRAP-positive osteoclasts in this region (Fig 2D). The inhibitory effects of W9
on osteoclastogenesis were milder than those of risedronate. These results suggest that the
increased number of osteoclasts in the M1 interradicular septum of OPG–/–mice is suppressed
by administration of W9 and risedronate.
W9 enhances osteoblastogenesis in alveolar bone ofOPG±/±mice
To elucidate effects of W9 on alveolar bone formation in OPG–/–mice, we evaluated the osteo-
blast number in the M1 interradicular septum (Fig 3A). The flat cells, identified as inactivated
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osteoblasts, were frequently observed in WT mice. Activated osteoblasts were identified as
cuboidal cells on bone surfaces in this region (black arrows) in OPG–/–mice. The osteoblast
number in the septum tended to be higher in OPG–/–mice than in WT mice (Fig 3A, Table 1).
The thickness of osteoblasts was also increased by approximately 2-fold in OPG–/–mice, com-
pared with WT mice. Administration of W9 to OPG–/–mice significantly increased the osteo-
blast number (Fig 3A, Table 1). The thickness of osteoblasts appeared to be increased by W9
administration (Fig 3A). In contrast, administration of risedronate to OPG–/–mice failed to
affect osteoblast number in the M1 interradicular septum (Table 1). Both MAR and bone for-
mation rate (BFR) were significantly higher in OPG–/–mice than WT mice (Table 1). Adminis-
tration of W9, but not risedronate, significantly increased both osteoblast surface and osteoid
surface (Table 1). These results suggest that bone formation in the M1 interradicular septum is
further accelerated in OPG–/–mice treated with W9.
Osterix is a master transcription factor for osteoblast differentiation expressed in osteogenic
cells [32]. We further examined bone formation in the M1 interradicular septum by immunos-
taining of osterix. The number of osterix-positive osteoblasts was significantly higher in
OPG–/–mice than in WT mice (Fig 3B and 3C). Administration of W9 to OPG–/–mice signifi-
cantly increased the number of the osterix-positive osteoblasts. In contrast, administration of
risedronate to OPG–/–mice significantly decreased the osterix-positive osteoblast number (Fig
3B and 3C). Immunostaining of ALP, a marker of osteoblasts, showed that expression of ALP
in the M1 interradicular septum was much stronger in OPG–/–mice than in WT mice (Fig 3D).
Administration of risedronate to OPG–/–mice suppressed ALP expression, suggesting that
osteoblast function was suppressed by treatment with risedronate. However, W9 administra-
tion failed to decrease ALP expression in osteoblasts in OPG–/–mice (Fig 3D). These findings
were supported by measurement of serum levels of ALP. The serum level of ALP was higher in
OPG–/–mice than in WT mice (Fig 3E). Administration of risedronate significantly decreased
the serum level of ALP in OPG–/–mice, while W9 did not (Fig 3E). These results suggest that
osteoblast differentiation in the M1 interradicular septum is accelerated in OPG–/–mice, and
that administration of W9, but not risedronate, to OPG–/–mice enhances osteoblast differentia-
tion in this region.
Table 1. Histomorphometric analysis of the protective effects of W9 on alveolar bone loss inOPG-/-mice.
Parameter - - W9 Risedronate
WT OPG-/- OPG-/- OPG-/-
B.Ar/T.Ar (%) 54.2±6.7 25.3±4.0a 37.1±3.1a, b 32.6±2.9a, b
N.OC/BS (N/mm) 0.6±0.3 6.8±2.6a 2.4±0.6b 2.6±0.6a, b
OC S/BS (%) 2.4±1.2 21.5±8.1a 9.4±3.2a, b 7.3±2.2b
N.OB/BS (N/mm) 19.0±4.7 25.4±5.0 49.4±6.4a, b 29.8±5.7a, c
OB S/BS (%) 24.4±6.2 25.8±6.2 52.0±4.7a, b 31.7±6.8c
MAR (μm/day) 2.0±0.3 3.8±0.7a 3.0±0.4a, b 3.1±0.4a, b
BFR/BS (mm3/mm2/year) 0.32±0.09 0.43±0.11a 0.45±0.05a 0.40±0.07
OS/BS (%) 31.6±7.4 41.3±7.6 69.6±5.8a, b 47.2±8.9a, c
Mlt. (day) 1.10±0.22 0.89±0.19 2.15±0.15a, b 1.34±0.25b, c
a) P < 0.05 versus vehicle treatedWT group,
b) P < 0.05 versus vehicle treatedOPG-/- group,
c) P < 0.05 versusW9 treatedOPG-/- group.
Bone area, B.Ar; Tissue area, T.Ar; Osteoclast number, N.Oc; Bone surface, BS; Osteoclast surface, Oc.S; Osteoblast number, N.Ob; Osteoblast surface,
Ob.S; Mineral apposition rate, MAR; Bone formation rate, BFR; Osteoid surface, OS; Mineralization lag time, Mlt.
https://doi.org/10.1371/journal.pone.0184904.t001
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Fig 3. Effects of W9 and risedronate administration on alveolar bone formation inOPG-/-mice. (A) Histological analysis of
the interradicular septum of the first molar (M1) in mandibles fromWT andOPG±/±mice treated with and withoutW9 or
risedronate. Mandible tissues were subjected to Villanueva bone staining. Mature osteoblasts were indicated by arrows. (B)
Osterix staining of maxillae fromWT andOPG±/±mice. Osterix-positive cells in nuclei (brown, arrows) were observed in theM1
interradicular septum in alveolar bone areas. (C) The number of osterix-positive cells/bone surface (N/mm) was determined in the
WP9QY peptide recovers alveolar bone loss
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W9 enhancesWnt/β-catenin signaling of alveolar bone inOPG±/±mice
To clarify the functional mechanisms of W9 on bone formation, we next examined the expres-
sion of β-catenin in alveolar bone in OPG–/–mice treated with W9 or risedronate, using immu-
nostaining with anti-β-catenin antibodies. β-catenin-positive signals on bone surfaces in the
M1 interradicular septum were stronger in OPG–/–mice than in WT mice (Fig 4A). Adminis-
tration of W9 to OPG–/–mice enhanced β-catenin-positive signals (Fig 4A). In contrast, admin-
istration of risedronate attenuated β-catenin-positive signals. These results suggest that Wnt/
β-catenin signaling is increased in OPG–/–mice, and W9 administration further enhances
Wnt/β-catenin signals in osteoblasts.
It was reported that the expression of sclerostin in osteocytes is lower in OPG–/–mice [25].
We finally examined whether the treatment with W9 affects the expression of sclerostin in
alveolar bone in OPG–/–mice using both immunostaining of sclerostin and histochemical
staining of TRAP. Administration of W9 to OPG–/–mice decreased the number of osteoclasts
(Fig 4B, also see Fig 2D). However, the sclerostin signal in osteocytes was rather suppressed by
W9 administration (Fig 4B and 4C). Administration of risedronate suppressed the osteoclast
number and enhanced sclerostin signals in osteocytes in OPG–/–mice (Fig 4B and 4C). Thus,
administration of W9, but not risedronate, to OPG–/–mice enhanced Wnt/β-catenin signaling
in alveolar bone through attenuation of sclerostin expression. These results suggest that
W9-induced suppression of sclerostin expression by osteocytes is independent of W9-induced
inhibition of osteoclastogenesis.
Discussion
In the present study, we demonstrated that treatment of OPG–/–mice with W9 restored their
alveolar bone loss through two independent mechanisms: One is suppression of osteoclasto-
genesis by inhibiting RANK signaling in osteoclast precursors, and the other is enhancement
of osteoblastogenesis by suppressing sclerostin expression in osteocytes. In addition to W9,
OP3-4, a cyclic peptide, to mimic OPG, was reported to bind to RANKL, thereby inhibiting
osteoclastogenesis [33]. OP3-4 could accelerate bone formation by affecting RANKL signaling
in osteoblasts in a similar manner to W9 [33]. These results suggest that RANKL-binding pep-
tides may have unique characteristics in the regulation of bone resorption and formation.
OPG–/–mice exhibited a high rate of bone turnover, in which bone formation was acceler-
ated with enhanced bone resorption [7, 9]. We have proposed that the primary cause of the
coupling phenomenon in OPG–/–mice is the regulation of sclerostin expression by osteocytes.
Sclerostin expression was maintained low in OPG–/–mice [24, 25]. When an anti-RANKL anti-
body was administered to OPG–/–mice, sclerostin expression in osteocytes was enhanced con-
comitantly with the suppression of osteoclastic bone resorption [24]. We have also shown that
osteoclasts secreted a factor which inhibited the expression of sclerostin in UMR 106 cells, an
osteoblast lineage cell line [24]. Present study showed that risedronate administration to
OPG–/–mice restored the expression level of sclerostin in osteocytes to that of WT mice. In
addition, clinical studies reported that bone resorption contributed to the bone turnover state
[18, 19] and was associated with the serum level of sclerostin [34–36]. Treatment with bisphos-
phonate suppressed bone turnover and increased serum sclerostin levels in postmenopausal
M1 interradicular septum (n = 5). (D) ALP staining of maxillae fromWT andOPG±/±mice. ALP-positive cells were observed in the
M1 interradicular septum in alveolar bone areas. (E) Serum ALP activities weremeasuredwith an ALP kit (n = 7). Data are
expressed as the mean ± SD in (C) and (E). *: p<0.05. Scale bar, 50 μm.
https://doi.org/10.1371/journal.pone.0184904.g003
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Fig 4. Effects of W9 and risedronate administration onWnt/β-catenin signaling of alveolar bone inOPG-/-mice. (A) Histological
analysis of the interradicular septum of the first molar (M1) in maxillae fromWT andOPG±/±mice treated with and withoutW9 or risedronate.
β-catenin staining of WT andOPG±/±mice. β-catenin-positive cells in nuclei (brown) were observed in the M1 interradicular septum in
alveolar bone areas. (B) Sclerostin and TRAP double staining of WT andOPG±/±mice. Sclerostin-positive osteocytes (brown) were
observed in theM1 interradicular septum in alveolar bone areas. Sclerostin-positive osteocytes are indicated by black arrows. (C) The
number of sclerostin-positive cells/bone area (N/mm2) was determined in the M1 interradicular septum (n = 5). Data are expressed as the
mean ± SD. *: p<0.05. Scale bar, 50 μm.
https://doi.org/10.1371/journal.pone.0184904.g004
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women [36]. These results suggest that the regulatory expression of sclerostin by osteocytes
plays a role in the coupling between bone resorption and formation in OPG–/–mice.
Administration of W9 as well as risedronate to OPG–/–mice suppressed bone resorption. W9
is reported to inhibit the RANKL-RANK interaction, similar to OPG. Indeed, W9 suppressed
osteoclast formation in bone marrow macrophage cultures treated with RANKL [28, 29]. W9
also inhibited survival of osteoclasts supported by RANKL but not by interleukin (IL) -1α (S1
Fig). W9 has been shown to get into a specific pocket in the RANKL-RANK binding structure
[28]. Thus, the inhibitory effects of W9 on osteoclastic bone resorption in OPG–/–mice may be
due to the inhibition of the RANKL-RANK interaction in osteoclast precursors.
In sharp contrast to risedronate, W9 administration did not suppress bone formation, but
keep low levels of sclerostin expression in OPG–/–mice. W9 added to UMR106 cell cultures
suppressed the secretion of sclerostin (data not shown). These results suggest that W9
enhances bone formation through the suppression of sclerostin expression in osteocytes. W9
was also reported to enhance the ectopic bone formation induced by BMP-2 [30]. BMP-
2-induced osteoblastic differentiation was up-regulated by W9 in C2C12 cell cultures. We
examined the effects of W9 on osteoblastic differentiation in OPG–/–calvarial osteoblasts in
vitro (S2 Fig). The intensity of W9-induced ALP activity and mineralization in OPG–/–calvarial
osteoblast cultures were equivalent to those in WT cultures. These results indicated that W9
induced osteoblast differentiation independently of OPG signaling. These results suggest that
W9 directly acts on osteoblasts and osteocytes to enhance bone formation.
It is proposed that W9 and OP3-4 bind to RANKL expressed on cell surfaces of osteoblasts
to induce retrograde signals [29, 33]. Up-regulation of the alkaline phosphatase expression by
these peptides was not clearly observed in osteoblasts derived from RANKL–/–mice in vitro
[29]. W9 and OP3-4 have been demonstrated to stimulate mammalian target of rapamycin
complex 1 (mTORC1) signaling in osteoblasts, which may be necessary for the RANKL-medi-
ated retrograde signals [33]. It was also reported that RANK-coated beads enhanced OPG
secretion by osteoblasts through the interaction between RANK expressed on beads and
RANKL expressed on osteoblasts [37]. These results suggest that W9 as well as RANK may
induce RANKL-mediated retrograde signals in osteoblasts to increase bone mass. OPG, which
most effectively binds to RANKL with very high affinity, did not exhibit such a reverse effect
on osteoblasts, suggesting that the binding formula of OP3-4 and W9 to RANKL may be dif-
ferent from that of OPG. Further experiments are necessary to elucidate the precise mecha-
nism of action of W9 in bone formation.
Administration of W9 to 12-week-old WT mice failed to increase BV/TV in M1 interradi-
cular septum, suggesting that W9 does not have a strong osteogenic effect, but rather has anti-
bone resorbing effects. In fact, administration of W9 to mice with calvarial defects promoted
bone formation in the presence of BMP-2, but not in the absence of BMP-2 [33]. Furthermore,
W9 protected ovariectomized- and low calcium diet- induced bone loss by suppressing bone
resorption [28]. These previous and the present studies suggest that, unlike risedronate, W9
does not inhibit bone formation with the suppression of bone resorption. Therefore, it is likely
that administration of W9 does not induce ectopic bone formation including osteophytes. Fur-
ther studies are needed to clarify the effects of W9 on ectopic bone formation.
The most important clinical feature of periodontal disease is loss of alveolar bone. It is an
urgent need in periodontal disease treatment to prevent alveolar bone loss. We have reported
that OPG–/–mouse exhibited a marked alveolar bone loss without infections [11]. The distance
between CEJ and ABC in OPG–/–mice was increased with time. Administration of risedronate
and anti-RANKL antibody to OPG–/–mice prevented alveolar bone loss and suppressed the
increase in the CEJ-ABC distance. These results suggest that antiresorptive agents can be ther-
apeutic agents for periodontitis. However, it is well known that antiresorptive agents induce
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osteonecrosis of the jaw in patients with cancer [38, 39]. Antiresorptive agents, such as bis-
phosphonates and anti-RANKL antibody, strongly inhibit bone formation as well as bone
resorption [9, 17–20, 24]. Inhibition of bone formation by these agents may be related to the
development of osteonecrosis of the jaw. W9 inhibited bone resorption, but still stimulated
bone formation to prevent alveolar bone loss in OPG–/–mice. Thus, the mechanism of W9 in
suppressing alveolar bone loss is different from that of antiresorptive agents. This suggests that
W9 can become a new therapeutic drug for osteoporosis. Indeed, parathyroid hormone, a
bone formation agent in osteoporosis, was reported to protect alveolar bone loss in animal and
human studies [40, 41]. Further studies are need to validate effects of W9 on alveolar bone loss
in periodontitis models.
In addition, W9 may exert some effects on inflammation in periodontitis models. Previous
studies have shown that the effect of W9 on bone formation was not stimulated by knockdown
of TNF-α and deficiency of TNF receptor type I [29, 30]. TNF-α-induced inflammation signals
are believed to be important signals for development of periodontal disease [42]. However,
effects of W9 on inflammations are important points for applying W9 to treatments of peri-
odontal disease.
In general, peptides have a short biological half-life due to their low stability in systemic cir-
culation [43]. Therefore, repetitive administration and larger dosage of peptides are needed to
obtain their effects. In fact, previous studies reported that the repetitive administration of W9
with high doses increased bone mass [28, 44]. In contrast, bisphosphonates including risedro-
nate are effective at small doses because they accumulated in bone matrices without degrada-
tion [45].
Furuya et al. [29] showed that W9 administration for 5 days increased cortical bone for-
mation in mice. We also showed that the short-term (for 5 days) treatment with W9 inhib-
ited bone resorption and promoted bone formation in alveolar bone of OPG–/–mice. Effects
of long-term treatment with W9 on alveolar bone and other tissues have not been evaluated
in the present study. The previous studies [28, 44] reported that long-term treatments
with W9 increased bone mass and promoted bone maturation without any adverse effect.
Therefore, the long-term treatment can be expected to further increase alveolar bone in
OPG–/–mice.
In conclusion, we demonstrated that administration of W9 effectively prevented alveolar
bone loss caused by OPG deficiency. We have proposed the possibility that beneficial effects of
W9 on bone are caused by two different mechanisms: suppression of RANK-mediated signals
in osteoclast precursors and enhancement of RANKL–mediated signals in osteocytes. Thus,
the effects of W9 on bone are quite unique. W9 may become a unique drug for treatment of
patients with osteoporosis and periodontitis. Further experiments using other bone loss mod-
els, such as ovariectomy and rheumatoid arthritis, are necessary for the development of W9 as
a drug for bone health.
Supporting information
S1 Fig. Effects of W9 on survival of osteoclasts supported by RANKL or IL-1α. Osteoblasts
obtained from mouse calvariae and bone marrow cells were co-cultured in the presence of
1,25-dihydroxyvitamin D3 (10
−8 M) and prostaglandin E2 (10
−6 M) in 100-mm diameter
dishes pre-coated with collagen gels (Nitta Gelatin, Osaka, Japan) [S1 Text, 1]. Osteoclasts
formed on day 7 were released from the dishes by treatment with 0.2% collagenase (Wako
Pure Chemical, Osaka). The crude osteoclast preparation was replaced on 24-well culture
plates for 5-hour culture. The plates were treated with with trypsin-EDTA to remove osteo-
blastic cells [S1 Text, 2]. Most of the remaining cells were multinucleated osteoclasts (purified
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osteoclast preparation). (A) Purified osteoclasts were further cultured in the presence or
absence of RANKL (200 ng/ml) or IL-1α (2.5 ng/ml). W9 (100 μM) was added to some cul-
tures. After culture for 40 hours, cells were stained for TRAP. (B) The number of TRAP-posi-
tive osteoclasts was counted before and after culture for 40 hours. The percentages of the
surviving osteoclasts were calculated. Data are expressed as the means ± SD. : p<0.05. Puri-
fied osteoclasts spontaneously died via apoptosis, and both RANKL and IL-1α promoted the
survival of osteoclasts. The survival of osteoclasts supported by RANKL but not by IL-1α was
suppressed by W9.
(TIF)
S2 Fig. Effects of W9 on ALP activity and mineralization of primary osteoblasts inOPG-/-
mice. Primary osteoblasts were prepared from newborn mouse calvariae from WT and
OPG–/–mice [S1 Text, 3]. (A) Osteoblasts (1 x 105 cells/well) were cultured in the presence of
100 μg/ml ascorbic acid and 5 mM β-glycerophosphate (Wako) in αMEM (Sigma, St. Louis,
MO) containing 10% fetal bovine serum (FBS) (JRH Biosciences, Lenexa, KS) in 6-well colla-
gen-coated plates (osteogenic culture conditions). The cultures were treated with or without
increasing concentrations of W9. After culture for 14 days, cells were processed for alkaline
phosphatase (ALP) staining. After culture for 21 days, cells were processed for alizarin red
staining as described previously [S1 Text, 4].
(TIF)
S3 Fig. Effects of W9 and risedronate administration on alveolar bone inWTmice. W9 or
risedronate was injected into 12-week-old WT mice. On day 6, bone volume/tissue volume
(BV/TV) of the first molar (M1) interradicular septum, a part of alveolar bone, was measured
by μCT images. (A) μCT images of the interradicular septum of the M1 in mandibles from
WT mice (an area surrounded by a white dotted line). (B) BV/TV was measured in the interra-
dicular M1 septum from WT mice treated with and without W9 or risedronate (n = 5). Data
are expressed as the mean ± SD in (B). Scale bar, 0.5 mm.
(TIF)
S1 Text. Supporting information references list.
(DOCX)
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